Article Information
History
- April 21, 2020.
Article Versions
- Version 1 (April 11, 2020 - 16:30).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jesse L. Carlin, Ph.D., Lead Clinical Scientist1,*,
- V. Rose Lieberman, Clinical Study Member1,
- Arya Dahal, Clinical Study Member1,
- Madison S. Keefe, Clinical Study Member1,
- Changfu Xiao, Head of Biometrics, Ph.D.,
- Gunther Birznieks, Research and Development Committee Member1,
- Thomas L. Abell, M.D.2,
- Anthony Lembo, Division of Gastroenterology, M.D.3,
- Henry P. Parkman, Department of Medicine, M.D.4 and
- Mihael H. Polymeropoulos, M.D.1, CEO, Research and Development Committee Member
- 1Vanda Pharmaceuticals, Inc., Washington, DC
- 2University of Louisville, Louisville, KY
- 3Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
- 4Temple University School of Medicine, Philadelphia, PA
- ↵*Correspondence:
Jesse L. Carlin, Vanda Pharmaceuticals, Inc., 2200 Pennsylvania Avenue NW, Suite 300-E, Washington D.C. 20037, Jesse.Carlin{at}vandapharma.com
Author Contributions: The conception and design of the study: Mihael H. Polymeropoulos, Gunther Birznieks, Changfu Xiao, and Jesse L. Carlin
Posted April 21, 2020.
Efficacy and Safety of Tradipitant in Diabetic and Idiopathic Gastroparesis: A Randomized, Placebo-Controlled Study
